Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1423-0380
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens ; volume:36 ; number:2 ; day:16 ; month:10 ; year:2014 ; pages:1003-1013 ; date:2.2015
Tumor biology ; 36, Heft 2 (16.10.2014), 1003-1013, 2.2015
- Urheber
-
Løes, Inger Marie
- Beteiligte Personen und Organisationen
-
Immervoll, Heike
Angelsen, Jon-Helge
Horn, Arild
Geisler, Jürgen
Busch, Christian
Lønning, Per Eystein
Knappskog, Stian
SpringerLink (Online service)
- DOI
-
10.1007/s13277-014-2711-5
- URN
-
urn:nbn:de:1111-2016112818454
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 14:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Løes, Inger Marie
- Immervoll, Heike
- Angelsen, Jon-Helge
- Horn, Arild
- Geisler, Jürgen
- Busch, Christian
- Lønning, Per Eystein
- Knappskog, Stian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
BRAF V600E mutations in nevi and melanocytic tumors of uncertain malignant potential (MELTUMPs)
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032
In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma
BRAF V600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
BRAF V600E mutations in nevi and melanocytic tumors of uncertain malignant potential (MELTUMPs)
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032
In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma
BRAF V600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
BRAF V600E mutations in nevi and melanocytic tumors of uncertain malignant potential (MELTUMPs)
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032
In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma
BRAF V600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?